MPA & Vasculitis GuideANCA vasculitis, starting with MPA and kidney disease
Urgent symptoms: when to get help now

Call 911 (or your local emergency number) for severe or sudden trouble breathing, coughing up blood, or heavy or spurting bleeding from a dialysis access.

Contact your care team promptly for new visible blood in urine, much less urine than usual, rapidly worsening swelling, fever while taking immune-suppressing medicine, being unable to keep transplant medicines down, or cloudy peritoneal dialysis fluid.

Follow the emergency plan your treating center gave you. More on urgent symptoms

How to read a study (plain language)

Types of evidence, weakest to strongest (roughly)

Trial phases

Phase 1 tests safety in a small group; phase 2 looks for signs of benefit and the right dose; phase 3 compares with standard care in a larger group. Registration tells you the question, not the answer.1,2

Numbers in one sentence each

Press releases, abstracts and retractions

A press release is not a result; companies choose what to highlight. Conference abstracts are short and not fully peer-reviewed. Even published trials can be retracted: the main avacopan trial paper was retracted in 2026.3 See avacopan.

Thinking about joining a trial?

Ask about eligibility (kidney function limits, transplant exclusions), costs and travel, placebo, how to withdraw, and how your data are protected. Talk with your own specialist first.1,2

Sources

  1. ClinicalTrials.gov: Learn about clinical studies
  2. NIH: NIH Clinical Research Trials and You: the basics
  3. PubMed record of NEJM notice (29 Jun 2026): Retraction: Jayne DRW et al. Avacopan for the treatment of ANCA-associated vasculitis (ADVOCATE) [doc ref 19]

Links checked 15 November 2026. Full list: all sources.